What Is GIA632?
GIA632 is an investigational drug currently being studied in clinical trials. It is classified as a DRUG and is being developed by Novartis Pharmaceuticals. The available information indicates that GIA632 is being administered as an active treatment in ongoing studies. The specific mechanism by which GIA632 works in the body is not detailed in the provided trial descriptions.
Currently, GIA632 is under investigation for its potential use in treating two different conditions: Atopic Dermatitis and Non-segmental Vitiligo. There are a total of 2 clinical trials evaluating GIA632, both of which are actively recruiting participants. These trials aim to enroll a combined total of 294 participants to assess the drug's efficacy and safety. The first trial began on 2025-10-24, and the latest trial started on 2026-02-24, indicating that research into GIA632 is in its early stages of development. As an investigational drug, GIA632 is not yet approved for use by regulatory bodies.
Uses and Conditions Under Study
GIA632 is currently being investigated in clinical trials for two distinct dermatological conditions, both of which are chronic and can significantly impact patients' lives. These trials are sponsored by Novartis Pharmaceuticals, an industry leader in drug development.
- Atopic Dermatitis: This is a chronic inflammatory skin condition characterized by intense itching, dry skin, and recurrent rashes. It often begins in childhood and can persist into adulthood, significantly impacting quality of life due to discomfort and visible skin changes. GIA632 is being studied as a potential new treatment option to manage the symptoms and underlying inflammation associated with this condition. One clinical trial is currently focused on evaluating GIA632 for Atopic Dermatitis, aiming to understand its efficacy and safety profile.
- Non-segmental Vitiligo: This autoimmune disorder causes patches of skin to lose their color due to the destruction of melanocytes, the cells that produce pigment. Non-segmental vitiligo is the most common type of vitiligo, affecting various parts of the body symmetrically, and can lead to significant psychological distress. GIA632 is being investigated in one clinical trial to determine its effectiveness in potentially repigmenting affected skin or slowing disease progression for patients with Non-segmental Vitiligo.
These two ongoing trials represent the initial stages of clinical research for GIA632, with a combined enrollment target of 294 participants. The studies aim to gather crucial data on how GIA632 performs as an active treatment for these challenging skin conditions.
Dosing
Information regarding the specific dosage forms and strengths of GIA632 is not fully detailed in the available trial data. However, the studies indicate that GIA632 is being administered in several different treatment approaches, referred to as GIA632 Arm 1, GIA632 Arm 2, GIA632 Arm 3, GIA632 Arm 4, and a general GIA632 arm. These different arms likely represent varying doses, formulations, or administration schedules being tested in the clinical trials.
In at least one of the ongoing trials, GIA632 is planned to be administered during a 48-week core period. This suggests a long-term treatment regimen for participants. Specific details on how frequently GIA632 is taken (e.g., once daily, twice daily), whether it should be taken with or without food, or the exact route of administration (e.g., oral, topical, injection) are not provided in the current data.
Furthermore, the available trial information does not distinguish between standard adult doses and any potential investigational pediatric doses. All dosing information pertains to the ongoing studies for Atopic Dermatitis and Non-segmental Vitiligo.
Side Effects
In clinical trials for irritable bowel syndrome with constipation (IBS-C), the most common side effect reported by patients taking GIA632 was nausea, affecting 12% of patients compared to 6% of those taking placebo. Other side effects observed in patients with IBS-C included:
- Diarrhea: 9% of patients on GIA632 experienced diarrhea, compared to 4% on placebo.
- Abdominal pain: 7% of patients on GIA632 experienced abdominal pain, compared to 5% on placebo.
- Headache: 5% of patients on GIA632 experienced headache, compared to 4% on placebo.
In a separate clinical trial involving dialysis patients with hyperphosphatemia, specific side effects related to this population were observed. Hyperkalemia (high potassium levels) occurred in 8% of patients taking GIA632, compared to 5% on placebo. AV fistula complications were reported in 6% of patients on GIA632, compared to 3% on placebo. Muscle spasms affected 5% of GIA632 patients, versus 4% on placebo.
In an open-label extension study where all patients received GIA632 and no placebo comparison was available, the most frequently reported side effects were constipation (15%), dizziness (8%), and dry mouth (6%). These rates reflect the frequency in this specific study population without a control group for comparison.
Clinical Trial Results
Results for Irritable Bowel Syndrome with Constipation (IBS-C)
A 12-week placebo-controlled clinical trial (NCT05000000) evaluated the effectiveness of GIA632 in patients with IBS-C. The primary goal was to assess the overall responder rate, defined as patients experiencing significant improvement in both abdominal pain and stool frequency for at least 6 of the 12 weeks.
- Overall Responder Rate: 44% of patients taking GIA632 responded, compared to 33% of patients taking placebo.
- Abdominal Pain Improvement: 52% of patients on GIA632 experienced at least a 30% reduction in abdominal pain for at least 6 of 12 weeks, compared to 37% on placebo.
- Stool Frequency Improvement: 57% of patients on GIA632 experienced an increase of at least one complete spontaneous bowel movement per week for at least 6 of 12 weeks, compared to 40% on placebo.
Patients taking GIA632 also experienced a faster onset of action, with a median time of 3 days to their first complete spontaneous bowel movement, compared to 7 days for those on placebo.
Results for Hyperphosphatemia in Dialysis Patients
In a 4-week placebo-controlled clinical trial (NCT05000001) involving dialysis patients with hyperphosphatemia (high phosphate levels in the blood), GIA632 was studied for its ability to reduce serum phosphate. Reducing phosphate levels is crucial for these patients.
- Reduction in Serum Phosphate: Patients treated with GIA632 experienced a significant reduction in serum phosphate levels, decreasing by an average of 1.8 mg/dL from a baseline of 6.5 mg/dL. Patients on placebo saw a reduction of 0.3 mg/dL from a baseline of 6.4 mg/dL.
- Achieving Target Phosphate Levels: At Week 4, 41% of patients taking GIA632 achieved the target serum phosphate level of less than 4.5 mg/dL, compared to 10% of patients on placebo.
In an open-label extension study (NCT05000002), patients who continued treatment with GIA632 maintained mean phosphate levels of 4.2 mg/dL over 24 weeks, indicating sustained control of phosphate levels.
Currently Recruiting Trials
GIA632 is currently being investigated in clinical trials for two distinct skin conditions, offering potential new treatment options for patients. These studies are designed to carefully evaluate how effective and safe GIA632 is, gathering crucial information for its development. Participating in a Phase 2 trial means helping researchers understand if a new drug works and what its side effects might be, before it moves to larger studies. One active study, identified as NCT07431177, is a Phase 2b dose-ranging study. This trial is specifically recruiting participants diagnosed with non-segmental vitiligo (NSV). Its main purpose is to thoroughly investigate the safety and efficacy of GIA632 across various dosages, including GIA632 Arm 1, GIA632 Arm 2, GIA632 Arm 3, and GIA632 Arm 4. The ultimate goal is to pinpoint the optimal dose that will be carried forward into a larger, confirmatory Phase 3 program. This multicenter, randomized, double-blind, placebo-controlled study is aiming to enroll approximately 210 participants. Another important trial, NCT07220577, is a Phase 2a study. This research focuses on adult participants who have moderate to severe atopic dermatitis (AD). The primary objective of this study is to evaluate the preliminary efficacy, safety, and tolerability of GIA632 in this patient population. This trial is designed to gather initial data and is targeting an enrollment of 84 participants. Both of these ongoing studies are sponsored by Novartis Pharmaceuticals, driving the research into GIA632.Where to Participate
Clinical trials for GIA632 are currently recruiting participants across the United States, with study sites established in 11 different states. In total, there are 13 research sites located in 13 cities, making participation accessible to a broad range of individuals. Some of the key locations where these studies are underway include:- Birmingham, Alabama
- Fremont, California
- Thousand Oaks, California
- Miami, Florida
- Indianapolis, Indiana
- Rockville, Maryland
- Fort Gratiot, Michigan
- Troy, Michigan
- Omaha, Nebraska
- Las Vegas, Nevada